Shop Now Contact

In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody

Cat # Size Price Quantity
5138011 mg$1750
5138025 mg$5950
51380325 mg$17850

  Bulk/Custom

Product Details

Clone10B4 / 10F.9G2
ApplicationFunctional assay, animal model study
Host SpeciesCHO cells
ReactivityMouse
FormatLiquid
Target NameCD370, C-type lectin family member 9A, PD-L1, PDL1 CD274, B7-H1
Product DescriptionIn Vivo Grade Recombinant Anti-mouse CD370 / PD-L1 Bispecific Antibody
IsotypeMouse IgG2c LALAPG Kappa
Antibody TypeRecombinant
Regulatory StatusRUO
Purity>95% by reducing SDS-PAGE
Endotoxin< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions4ºC
GradeIn vivo
Recommended UsageThis product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
Research AreasConventional Dendritic cells (cDC1s), CD16 Monocytes
See All FormatsClone 10B4 / 10F.9G2

Background Information

CD370, also known as CLEC9A (C-type lectin domain family 9 member A), is a receptor primarily expressed on a specialized subset of dendritic cells known as CD141⁺ (BDCA3⁺) dendritic cells in humans. These cells play an essential role in the cross-presentation of antigens, a process by which exogenous antigens are presented on MHC class I molecules to activate cytotoxic CD8⁺ T cells. Structurally, CD370 is a type II transmembrane glycoprotein with a single extracellular C-type lectin-like domain and a short cytoplasmic tail containing an immunoreceptor tyrosine-based activation motif (ITAM-like) that transmits activation signals through the SYK kinase pathway. Functionally, it recognizes exposed actin filaments from necrotic or damaged cells, enabling dendritic cells to uptake and process antigens from dying cells, initiating robust T cell–mediated immune responses.

PD-L1 (Programmed Death-Ligand 1, also known as CD274) is an immune checkpoint molecule expressed on various immune and tumor cells. It interacts with its receptor PD-1 on T cells to inhibit T cell activation, proliferation, and cytokine production, thereby maintaining immune tolerance and preventing autoimmunity. However, many tumors exploit this pathway by overexpressing PD-L1 to suppress anti-tumor immunity and evade immune destruction. Hence, the PD-1/PD-L1 axis has become a central target in cancer immunotherapy, with monoclonal antibodies like pembrolizumab and atezolizumab already benefiting patients across multiple cancer types.

Combining CD370 and PD-L1 in a single bispecific antibody offers a synergistic therapeutic strategy that unites immune activation with checkpoint blockade. A bispecific antibody targeting CD370 could specifically target and deliver immune-stimulating signals or antigen payloads directly to cross-presenting dendritic cells, enhancing their ability to prime CD8⁺ T cells. Simultaneously, engagement of PD-L1 blockade would relieve inhibitory signals in the tumor microenvironment, sustaining this T cell activation. Such a dual-target approach could bridge innate and adaptive immunity, reinvigorating existing T cells while recruiting new ones through enhanced antigen presentation. Additionally, the localized targeting of dendritic cells may reduce systemic immune-related toxicities often seen with global checkpoint inhibition. Overall, a CD370 × PD-L1 bispecific antibody could potentiate anti-tumor immunity by turning immunologically “cold” tumors into “hot” ones, maximizing T cell activation and persistence while minimizing off-target effects, representing a promising direction in next-generation cancer immunotherapies.

Data Sheets

In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody TDS

Related Products

Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Biotin Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2

Anti-Human PD-L1 (Atezolizumab Biosimilar), Clone Atezolizuma

Anti-Human PD-L1 (Avelumab Biosimilar), Clone Avelumab

Human PD-L1 (CD274) Protein (C-His)

Human PD-L1 (CD274) Protein (C-His-Avi)

Biotin Human PD-L1 (CD274) Protein (C-His-Avi)

PE Human PD-L1 (CD274) Protein (C-His)

APC Human PD-L1 (CD274) Protein (C-His)

Human PD-L1 (CD274) Protein (C-Fc)

Frequently Asked Questions

What are In Vivo Star Biofunctional Antibodies?
In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.
How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?
Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.
What endotoxin and purity specifications do these antibodies meet?
All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.
Are these antibodies azide-free and carrier-free?
All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.
Do you provide isotype controls?
Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.
How should In Vivo Star antibodies be stored and handled?
Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.